J&J’s New Innovation Centers Test Immersion Theory Of Access
Executive Summary
Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?
You may also be interested in...
J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.
Deals of the Week Plays Favorites: Our Deals Of The Year Winners!
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
J&J Tries Transitioning To Health Care Solutions Firm Through JHI Subsidiary
The healthcare conglomerate has been testing out-of-the-box ways to address current key challenges for its stakeholders, namely improving the patient experience, reducing the cost-burden to the health care system, and ultimately enhancing the marketplace in which it sells its products.